Bill Gates backs Schrödinger's $85M venture raise for its standout computational drug discovery platform
Computational chemistry in drug discovery is nothing new — the idea that more precise molecular design can speed up and optimize R&D is always appealing to an industry desperate for a higher return of investment — but it might just be gaining steam again. Just look at the list of investors in Schrödinger’s latest round.
Deerfield Management, Baron, Qiming Venture Partners, and GV (formerly Google Ventures) all chipped into the $85 million Series E, co-led by two of Schrödinger’s big believers: Bill Gates, who’s supported previous rounds; and WuXi AppTec, which launched a drug discovery joint venture with the company just weeks ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.